Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Retina Consultants of Nevada
mi
from
Las Vegas, NV
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Retina Consultants of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Delaware Valley Retina Associates
mi
from
Lawrenceville, NJ
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Delaware Valley Retina Associates
mi
from
Lawrenceville, NJ
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
NJ Retina
mi
from
New Brunswick, NJ
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
NJ Retina
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
New York Eye & Ear Infirmary
mi
from
New York, NY
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
New York Eye & Ear Infirmary
mi
from
New York, NY
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Retina Associates of Western New York
mi
from
Rochester, NY
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Retina Associates of Western New York
mi
from
Rochester, NY
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
University of Rochester - Flaum Eye Institute
mi
from
Rochester, NY
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
University of Rochester - Flaum Eye Institute
mi
from
Rochester, NY
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Retina Vitreous Surgeon of CNY, PC
mi
from
Syracuse, NY
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Retina Vitreous Surgeon of CNY, PC
mi
from
Syracuse, NY
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Charlotte Eye, Ear, Nose & Throat Associates
mi
from
Charlotte, NC
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Charlotte Eye, Ear, Nose & Throat Associates
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Charlotte Eye Ear Nose & Throat Associates, P.A.
mi
from
Statesville, NC
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Charlotte Eye Ear Nose & Throat Associates, P.A.
mi
from
Statesville, NC
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Retina Associates of Cleveland
mi
from
Cleveland, OH
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Retina Associates of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Dean McGee Eye Institute
mi
from
Oklahoma City, OK
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Dean McGee Eye Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Casey Eye Institute/OHSU
mi
from
Portland, OR
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Casey Eye Institute/OHSU
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Retina Northwest, PC
mi
from
Portland, OR
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Retina Northwest, PC
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Retina Vitreous Consultants
mi
from
Monroeville, PA
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Retina Vitreous Consultants
mi
from
Monroeville, PA
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Scheie Eye Institute
mi
from
Philadelphia, PA
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Scheie Eye Institute
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Carolinas Centers for Sight, PC
mi
from
Florence, SC
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Carolinas Centers for Sight, PC
mi
from
Florence, SC
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Palmetto Retina Center
mi
from
West Columbia, SC
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Palmetto Retina Center
mi
from
West Columbia, SC
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Black Hills Regional Eye Institute
mi
from
Rapid City, SD
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Black Hills Regional Eye Institute
mi
from
Rapid City, SD
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Southeastern Retina Associates, P.C.
mi
from
Knoxville, TN
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Southeastern Retina Associates, P.C.
mi
from
Knoxville, TN
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Tennessee Retina, P.C.
mi
from
Nashville, TN
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Tennessee Retina, P.C.
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Vanderbilt Eye Institute
mi
from
Nashville, TN
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Vanderbilt Eye Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Retina Research Institute of Texas, LLC
mi
from
Abilene, TX
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Retina Research Institute of Texas, LLC
mi
from
Abilene, TX
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Texas Retina Associates
mi
from
Arlington, TX
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Texas Retina Associates
mi
from
Arlington, TX
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Retina Research Center
mi
from
Austin, TX
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Retina Research Center
mi
from
Austin, TX
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Texas Retina Associates
mi
from
Dallas, TX
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Texas Retina Associates
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Charlotte Eye Ear Nose & Throat Associates, P.A.
mi
from
Houston, TX
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Charlotte Eye Ear Nose & Throat Associates, P.A.
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Retina and Vitreous of Texas
mi
from
Houston, TX
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Retina and Vitreous of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Retina Consultants of Houston
mi
from
Houston, TX
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Retina Consultants of Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Valley Retina Institute, P.A.
mi
from
McAllen, TX
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Valley Retina Institute, P.A.
mi
from
McAllen, TX
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Medical Center Ophthalmology Associates
mi
from
San Antonio, TX
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Medical Center Ophthalmology Associates
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Retinal Consultants of San Antonio
mi
from
San Antonio, TX
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Retinal Consultants of San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Retina Group of Washington
mi
from
Fairfax, VA
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Retina Group of Washington
mi
from
Fairfax, VA
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin
mi
from
Madison, WI
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Retina Group of Florida
mi
from
Fort Lauderdale, FL
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Retina Group of Florida
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Retina Associates, PA
mi
from
Shawnee Mission, KA
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Retina Associates, PA
mi
from
Shawnee Mission, KA
Click here to add this to my saved trials
Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema
An Exploratory, Multi-Center, Randomized, Single-Masked Study Evaluating the Effect of KPI-121 on Intraretinal or Subretinal Fluid Secondary to Retinal Vein Occlusion or Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Ophthalmic Consultants of Boston
mi
from
Boston, MA
Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema
An Exploratory, Multi-Center, Randomized, Single-Masked Study Evaluating the Effect of KPI-121 on Intraretinal or Subretinal Fluid Secondary to Retinal Vein Occlusion or Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Ophthalmic Consultants of Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema
An Exploratory, Multi-Center, Randomized, Single-Masked Study Evaluating the Effect of KPI-121 on Intraretinal or Subretinal Fluid Secondary to Retinal Vein Occlusion or Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Retina-Vitreous Associates Medical Group
mi
from
Beverly Hills, CA
Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema
An Exploratory, Multi-Center, Randomized, Single-Masked Study Evaluating the Effect of KPI-121 on Intraretinal or Subretinal Fluid Secondary to Retinal Vein Occlusion or Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Retina-Vitreous Associates Medical Group
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Uni of Alabama At Birmingham Clinical Research Unit
mi
from
Birmingham, AL
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Uni of Alabama At Birmingham Clinical Research Unit
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Retinal Research Institute LLC
mi
from
Phoenix, AZ
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Retinal Research Institute LLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Retina Centers, P.C.
mi
from
Tucson, AZ
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Retina Centers, P.C.
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
California Retina Consultants
mi
from
Bakersfield, CA
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
California Retina Consultants
mi
from
Bakersfield, CA
Click here to add this to my saved trials
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Retina-Vitreous Associates Medical Group
mi
from
Beverly Hills, CA
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Retina-Vitreous Associates Medical Group
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
The Gavin Herbert Eye Institute/UC Irvine
mi
from
Irvine, CA
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
The Gavin Herbert Eye Institute/UC Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Jules Stein Eye Institute, UCLA
mi
from
Los Angeles, CA
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Jules Stein Eye Institute, UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
East Bay Retina Consultants, Inc.
mi
from
Oakland, CA
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
East Bay Retina Consultants, Inc.
mi
from
Oakland, CA
Click here to add this to my saved trials